Breaking News Instant updates and real-time market news.

CELG

Celgene

$94.39

2.41 (2.62%)

09:38
02/15/18
02/15
09:38
02/15/18
09:38

Celgene says OTEZLA data shows 'clinically meaningful improvements' in patients

Celgene Corporation announced that data from a randomized, placebo-controlled, multi-center, phase II clinical trial of apremilast in patients with active ulcerative colitis who had failed at least one conventional therapy but were naive to biologic therapy were presented in an oral session today at the 13th Congress of ECCO in Vienna. The results showed that a higher proportion of patients taking apremilast 30 mg twice daily achieved clinical remission versus placebo. OTEZLA is Celgene's oral selective inhibitor of phosphodiesterase 4. In the study, a total of 170 patients were randomized to placebo, apremilast 40 mg BID or apremilast 30 mg BID. The primary endpoint of the study was Total Mayo Score clinical remission at week 12 for the 40 mg BID arm. At week 12, TMS clinical remission was achieved by 21.8% of patients in the apremilast 40 mg BID arm versus 13.8% in the placebo group. In the apremilast 30 mg BID arm, 31.6% of patients achieved clinical remission as measured by TMS at week 12 versus 13.8% in the placebo group. Clinical remission as measured by Partial Mayo Score, a secondary endpoint, was achieved by 59.6% of patients in the apremilast 30 mg BID arm versus 36.2% in the placebo arm at week 12. PMS clinical remission was also achieved by 52.7% of patients in the apremilast 40 mg BID arm. Additional secondary endpoints examined in the trial, including endoscopic remission, TMS clinical response, serum biomarkers and mucosal healing, showed clinically meaningful improvements for apremilast 30 mg BID versus placebo. Treatment-emergent adverse events reported in at least 5% of patients treated with apremilast included headache; viral upper respiratory tract infection; nausea; abdominal pain; back pain; and asthenia. Apremilast is not approved for the treatment of ulcerative colitis in any country. In January 2018, the U.S. Food and Drug Administration designated apremilast an Orphan Drug for the potential treatment of pediatric patients with ulcerative colitis.

  • 15

    Feb

  • 16

    Feb

  • 21

    Feb

  • 25

    Mar

  • 30

    May

CELG Celgene
$94.39

2.41 (2.62%)

02/13/18
02/13/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. JPMorgan (JPM) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Brian Kleinhanzl saying he views the recent pullback in the shares as a buying opportunity. 2. Total (TOT) upgraded to Overweight from Equal Weight at Morgan Stanley and to Strong Buy from Outperform at Raymond James. 3. Celgene (CELG) upgraded to Overweight from Equal Weight at Barclays with analyst Geoff Meacham saying the current valuation largely reflects the risk. 4. Quest Diagnostics (DGX) upgraded to Outperform from Neutral at Credit Suisse with analyst A.J. Rice saying he believes the company has "substantial runway on several fronts," including its Optum partnership related to revenue cycle management, which he believes could reduce bad debts and claims denials. 5. Boeing (BA) upgraded to Buy from Hold at Edward Jones. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/13/18
LEHM
02/13/18
UPGRADE
Target $105
LEHM
Overweight
Celgene upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Geoff Meacham upgraded Celgene to Overweight with an unchanged price target of $105. The analyst remains concerned about Revlimid concentration risk long-term, but says the current valuation largely reflects the risk. Since the highs in October 2017, the stock has dropped $55 per share, Meacham tells investors in a research note. He notes Celgene's risk/reward profile based on his net present value analysis yields an "attractive upside case."
02/09/18
PIPR
02/09/18
NO CHANGE
PIPR
Piper Jaffray reiterates Outperform on Crispr after CSO departure
Piper Jaffray analyst Edward Tenthoff reiterated an Outperform rating and $39 price target on Crispr Therapeutics, despite Crispr trading down over 13% on news that Dr. Bill Lundberg is stepping down as Chief Scientific Officer and Celgene (CELG) has reduced its stake in the company to 6.1% from 8.0%. Tenthoff said he remains focused on Crispr's "therapeutic opportunity with first-in-man CTX001 Beta thalassemia and potentially sickle cell disease data this year."
01/29/18
WELS
01/29/18
NO CHANGE
Target $23
WELS
Outperform
Iovance Biotherapeutics price target raised to $23 from $17.50 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Iovance Biotherapeutics (IOVA) to $23 following feedback from a "prominent cell therapy expert" late last week. The expert described expanding capacity for Gilead's (GILD) Yescarta, skepticism on Celgene (CELG) and Juno Therapeutics' (JUNO) claims around broad outpatient CAR-T opportunity for JCAR17, and a preference for tumor infiltrating lymphocyte therapeutics from Iovance for solid tumors over T-Cell receptor therapeutics being developed by a large number of companies, Birchenough tells investors in a research note. He reiterates Outperform ratings on both Iovance and Gilead.

TODAY'S FREE FLY STORIES

TLND

Talend

$49.40

-1.81 (-3.53%)

09:36
03/25/19
03/25
09:36
03/25/19
09:36
Recommendations
Talend analyst commentary  »

Talend price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHI

Robert Half

$63.78

-2.58 (-3.89%)

09:36
03/25/19
03/25
09:36
03/25/19
09:36
Hot Stocks
Breaking Hot Stocks news story on Robert Half »

Robert Half mentioned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$109.51

-2.68 (-2.39%)

09:35
03/25/19
03/25
09:35
03/25/19
09:35
Downgrade
Texas Instruments rating change  »

Texas Instruments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

TXN

Texas Instruments

$109.51

-2.68 (-2.39%)

09:33
03/25/19
03/25
09:33
03/25/19
09:33
Downgrade
Texas Instruments rating change  »

Texas Instruments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

LNTH

Lantheus

$23.61

-1.575 (-6.25%)

09:33
03/25/19
03/25
09:33
03/25/19
09:33
Hot Stocks
Lantheus promotes John Bolla to COO »

Lantheus announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

MEOH

Methanex

$57.73

-2.64 (-4.37%)

09:33
03/25/19
03/25
09:33
03/25/19
09:33
Hot Stocks
M&G Investments announces four director nominees for Methanex board »

M&G Investments, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHI

D.R. Horton

$41.28

0.75 (1.85%)

09:32
03/25/19
03/25
09:32
03/25/19
09:32
Recommendations
D.R. Horton analyst commentary  »

D.R. Horton benefiting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

LNTH

Lantheus

$23.61

-1.575 (-6.25%)

09:31
03/25/19
03/25
09:31
03/25/19
09:31
Hot Stocks
Lantheus announces upcoming retirement of Chief Medical Officer in September »

Lantheus Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

NEON

Neonode

$2.80

(0.00%)

09:28
03/25/19
03/25
09:28
03/25/19
09:28
Hot Stocks
Neonode says Convergence Promotions to act as sales and marketing partner »

Neonode announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLXP

PLx Pharma

$5.54

-0.525 (-8.66%)

09:27
03/25/19
03/25
09:27
03/25/19
09:27
Syndicate
Breaking Syndicate news story on PLx Pharma »

PLx Pharma files $75M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEX

Wex

$184.59

-6.555 (-3.43%)

09:26
03/25/19
03/25
09:26
03/25/19
09:26
Hot Stocks
Wex to acquire fuel card business of EG Group »

WEX announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IART

Integra LifeSciences

$55.29

-2.07 (-3.61%)

09:25
03/25/19
03/25
09:25
03/25/19
09:25
Conference/Events
Integra LifeSciences participates in a conference call with JPMorgan »

Medical Supplies &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

PTI

Proteostasis

$4.17

-0.14 (-3.25%)

, VRTX

Vertex

$181.49

-1.07 (-0.59%)

09:25
03/25/19
03/25
09:25
03/25/19
09:25
Recommendations
Proteostasis, Vertex analyst commentary  »

Piper sees 'clear…

PTI

Proteostasis

$4.17

-0.14 (-3.25%)

VRTX

Vertex

$181.49

-1.07 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 10

    Apr

09:25
03/25/19
03/25
09:25
03/25/19
09:25
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

09:25
03/25/19
03/25
09:25
03/25/19
09:25
General news
A Spring Rebound for Producer Sentiment »

A Spring Rebound for…

09:25
03/25/19
03/25
09:25
03/25/19
09:25
Conference/Events
The U.S. Commodity Futures Trading Commission to hold a meeting »

Open Commission Meeting…

ORGS

Orgenesis

$5.01

-0.19 (-3.65%)

09:24
03/25/19
03/25
09:24
03/25/19
09:24
Hot Stocks
Orgenesis to establish new facility for cell, gene therapy manufacturing »

Orgenesis announced plans…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVP

Avon Products

$3.06

0.28 (10.07%)

09:24
03/25/19
03/25
09:24
03/25/19
09:24
Recommendations
Avon Products analyst commentary at DA Davidson »

Avon Products buyout…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSL

MidSouth Bancorp

$10.22

-0.49 (-4.58%)

09:23
03/25/19
03/25
09:23
03/25/19
09:23
Upgrade
MidSouth Bancorp rating change  »

Sandler O'Neill says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:21
03/25/19
03/25
09:21
03/25/19
09:21
Conference/Events
JPMorgan retail analyst to hold an analyst/industry conference call »

Broadlines &…

PLAN

Anaplan

$38.98

-1.47 (-3.63%)

09:21
03/25/19
03/25
09:21
03/25/19
09:21
Initiation
Anaplan initiated  »

Anaplan initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDOR

Condor Hospitality Trust

$8.70

(0.00%)

09:19
03/25/19
03/25
09:19
03/25/19
09:19
Hot Stocks
Condor Hospitality Trust announces sale of non-core legacy hotel »

Condor Hospitality Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
03/25/19
03/25
09:18
03/25/19
09:18
Options
Overnight activity included 349 trades in SPX and 231 trades in VIX »

349 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTDR

Frontdoor

$32.78

0.38 (1.17%)

09:16
03/25/19
03/25
09:16
03/25/19
09:16
Initiation
Frontdoor initiated  »

Frontdoor initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$79.94

-1.29 (-1.59%)

09:15
03/25/19
03/25
09:15
03/25/19
09:15
Downgrade
AbbVie rating change  »

AbbVie downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 18

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.